Evolution of the Average Target: Merck & Co., Inc.

Evolution of the Target Price: Merck & Co., Inc.

Changes in Analyst Recommendations: Merck & Co., Inc.

ffc981a.Rkr7HnTTlBZU0rUmydRZa_RZ8PagxsaZXe5w9NR1XtQ.BSbMdz2i-F8dtNEfgLxrWoEAwKz4lPHPFJRBhpoULeQwGrlJO5indDeV2g~92f8cb85f617cbbc832fef8890219d30
Jan. 22 JPMorgan Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Overweight Rating MT
Jan. 20 TD Cowen Adjusts Price Target on Merck to $120 From $100, Maintains Hold Rating MT
Jan. 20 Leerink Partners Adjusts Price Target on Merck to $124 From $114, Maintains Outperform Rating MT
Jan. 09 Morgan Stanley Adjusts Price Target on Merck to $101 From $102, Maintains Equalweight Rating MT
Jan. 09 Morgan Stanley Trims Price Target on Merck to $101 From $102, Keeps Equalweight Rating MT
Jan. 08 Merck Shares Rise After Wolfe Research Upgrade MT
Jan. 08 Rothschild & Co Redburn Adjusts Merck Price Target to $135 From $125, Maintains Buy Rating MT
Jan. 08 Wolfe Research Upgrades Merck & Co. to Outperform From Peer Perform, Price Target is $135 MT
Jan. 07 UBS Adjusts Price Target on Merck & Co to $130 From $105, Maintains Buy Rating MT
Jan. 05 Exelixis Faces Limited High-Impact Catalysts, BofA Says MT
Dec. 18 BMO Capital Upgrades Merck & Co. to Outperform From Market Perform, Adjusts PT to $130 From $82 MT
Dec. 18 Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron… Zonebourse
Dec. 17 Deutsche Bank Adjusts Price Target on Merck to $115 From $111, Maintains Hold Rating MT
Dec. 15 Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says MT
Dec. 12 Morgan Stanley Adjusts Merck & Co. PT to $102 From $100, Maintains Equalweight Rating MT
Dec. 10 HSBC Adjusts Price Target on Merck & Co. to $120 From $100, Maintains Buy Rating MT
Dec. 05 Guggenheim Adjusts Price Target on Merck & Co. to $122 From $104, Maintains Buy Rating MT
Dec. 04 Scotiabank Adjusts Price Target on Merck & Co to $120 From $105, Maintains Sector Outperform Rating MT
Dec. 01 Goldman Sachs Adjusts Price Target on Merck to $120 From $92, Maintains Buy Rating MT
Nov. 24 Wells Fargo Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $125 From $90 MT
Nov. 19 Berenberg Adjusts Price Target on Merck & Co. to $95 From $90, Maintains Hold Rating MT
Nov. 19 Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Buy Rating MT
Nov. 19 Berenberg Raises Price Target on Merck to $95 From $90, Keeps Hold Rating MT
Nov. 19 Jefferies Adjusts Price Target on Merck & Co. to $139 From $138, Maintains Buy Rating MT
Nov. 18 Deutsche Bank Lifts Price Target on Merck to $111 From $110, Keeps Hold Rating MT
More recommendations

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.61%
+4.36%
+1.79%
+11.84%
-1.68%
+10.85%
-3.9%
+0.74%
-3.82%
-1.03%
Average +2.58%
Weighted average by Cap. +3.27%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
108.18USD
Average target price
115.33USD
Spread / Average Target
+6.61%
High Price Target
135.00USD
Spread / Highest target
+24.79%
Low Price Target
83.00USD
Spread / Lowest Target
-23.28%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMorgan Chase
TD Cowen
Leerink Partners
Morgan Stanley
Rothschild & Co Redburn
Wolfe Research
UBS
BMO Capital
Deutsche Bank Securities
HSBC
Guggenheim
Scotiabank
Goldman Sachs
Wells Fargo Securities
Berenberg Bank
Jefferies & Co.
DBS Bank
Daiwa Securities
Cantor Fitzgerald
Citigroup
Redburn Atlantic
Bernstein
Truist Securities
CFRA
Argus
Barclays
Zacks Investment Research
Societe Generale
BofA Securities
Atlantic Equities
Credit Suisse
SVB Securities LLC
Cowen
SVB Leerink
RBC Capital Markets
RBC Randall Stanicky
JPMORGAN
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
108.18USD
Average target price
115.33USD
Spread / Average Target
+6.61%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Consensus Merck & Co., Inc.